SLT Holdings LLC Makes New Investment in TransMedics Group, Inc. $TMDX

Key Points

• SLT Holdings LLC has made a new investment in TransMedics Group, purchasing 2,493 shares valued at approximately $334,000.
• TransMedics Group reported earnings of $0.92 per share for the last quarter, significantly surpassing analysts' expectations of $0.48, with a year-over-year revenue increase of 37.7%.
• Analysts have set a consensus target price of $125.40 for TransMedics Group, with ratings ranging from "Buy" to "Hold" from several brokerages.

SLT Holdings LLC purchased a new stake in TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 2,493 shares of the company's stock, valued at approximately $334,000.

Several other institutional investors and hedge funds also recently modified their holdings of TMDX. NBC Securities Inc. purchased a new stake in shares of TransMedics Group in the first quarter valued at about $25,000. Opal Wealth Advisors LLC purchased a new stake in shares of TransMedics Group in the second quarter valued at about $26,000. Smartleaf Asset Management LLC lifted its holdings in shares of TransMedics Group by 44.3% in the first quarter. Smartleaf Asset Management LLC now owns 440 shares of the company's stock valued at $30,000 after purchasing an additional 135 shares in the last quarter. Quarry LP lifted its holdings in shares of TransMedics Group by 88.5% in the first quarter. Quarry LP now owns 592 shares of the company's stock valued at $40,000 after purchasing an additional 278 shares in the last quarter. Finally, Sound Income Strategies LLC purchased a new stake in shares of TransMedics Group in the second quarter valued at about $48,000. Hedge funds and other institutional investors own 99.67% of the company's stock.

TransMedics Group Stock Performance

Shares of TMDX opened at $107.29 on Friday. The company has a debt-to-equity ratio of 1.61, a quick ratio of 9.17 and a current ratio of 9.86. The company has a market capitalization of $3.66 billion, a price-to-earnings ratio of 55.59 and a beta of 2.08. The company's 50 day simple moving average is $117.21 and its 200 day simple moving average is $111.82. TransMedics Group, Inc. has a 1 year low of $55.00 and a 1 year high of $145.50.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last posted its quarterly earnings results on Wednesday, July 30th. The company reported $0.92 earnings per share for the quarter, topping analysts' consensus estimates of $0.48 by $0.44. The company had revenue of $157.37 million for the quarter, compared to the consensus estimate of $146.64 million. TransMedics Group had a net margin of 13.49% and a return on equity of 28.02%. TransMedics Group's revenue was up 37.7% on a year-over-year basis. During the same quarter last year, the firm posted $0.35 earnings per share. TransMedics Group has set its FY 2025 guidance at EPS. On average, sell-side analysts predict that TransMedics Group, Inc. will post 1 EPS for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on TMDX. Stifel Nicolaus began coverage on shares of TransMedics Group in a report on Thursday, September 4th. They issued a "hold" rating and a $115.00 price target on the stock. Weiss Ratings reaffirmed a "hold (c)" rating on shares of TransMedics Group in a report on Wednesday. Morgan Stanley upped their price target on shares of TransMedics Group from $115.00 to $123.00 and gave the company an "equal weight" rating in a report on Friday, August 1st. Evercore ISI initiated coverage on shares of TransMedics Group in a research note on Tuesday, September 16th. They set an "outperform" rating and a $155.00 price objective on the stock. Finally, Wall Street Zen downgraded shares of TransMedics Group from a "buy" rating to a "hold" rating in a research note on Saturday, August 30th. Six investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $125.40.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.

Want to see what other hedge funds are holding TMDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TransMedics Group, Inc. (NASDAQ:TMDX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.